None listed
Conditions
Brief summary
While many childhood cancers can be treated with standard therapies that have proved to be effective, in some cases, children with cancer might benefit from treatments that match their tumour characteristics. These treatments are known as personalised medicine. Information about personalised medicine for childhood cancer can be found in two main sources: clinical trials and medical literature. The process of determining the best drug, or combination of drugs, for a child can be challenging because there is an ever-growing collection of both of these sources. The process of sorting through hundreds of search results is very time consuming and requires highly specialised knowledge. This means that finding the best treatment can be a complex process, which can make it difficult to choose the best treatment for each child. In this study, we are partnering with researchers in CSIRO to develop Oncology Search Clinical Assistant Registry (OSCAR), a search tool designed to help paediatric oncologist find personalised treatments for childhood cancer. Study Details: What does participation in this research involve for my child? A. Allowing your child’s Molecular Profiling results from ZERO2 to be used to evaluate OSCAR: Your consent will allow ZERO2 clinicians to use your child’s ZERO2 results to evaluate the OSCAR search-engine. Clinicians trying to find adequate treatment for your child will do side-by-side comparisons of results doing manual searches with results obtained using the OSCAR search-engine. There are no costs associated with participating in this research project, nor will you or your child be paid. Who is it for? You may be eligible for this study if you are a child who has been diagnosed with cancer and has been enrolled on one of the studies led by the ZERO Childhood Cancer Program (ZERO2/PRISM). We hope this study will: • Compare the quality of results generated by OSCAR to results obtained by doing manual searches. • Determine if OSCAR can help save time when searching for personalised treatments for childhood cancer.
Interventions
OSCAR is a search engine designed to facilitate treatment matching for children with cancer who have undergone molecular profiling of their tumour tissue and germline.
This study aims to evaluate OSCAR using a two-phase approach:
1) An initial validation phase, using reports generated as part of the ZERO Childhood Cancer Program platform to validate and train the algorithm. Data collected during the validation phase will include the results generated by the search-engine, number of results and
OSCAR is a search engine designed to facilitate treatment matching for children with cancer who have undergone molecular profiling of their tumour tissue and germline. This study aims to evaluate OSCAR using a two-phase approach: 1) An initial validation phase, using reports generated as part of the ZERO Childhood Cancer Program platform to validate and train the algorithm. Data collected during the validation phase will include the results generated by the search-engine, number of results and how many results match those found by manual searches; and 2) A user evaluation phase aiming to work alongside curation clinicians that will trial OSCAR and compare workload by using the search-engine, and provide qualitative reports of their user experience. Workload is defined by time spent performing treatment matching and user experience (OSCAR's ease of use, training time, etc). The initial validation phase will be completed after all existing eligible reports have been used by the CSIRO to validate and train the OSCAR algorithm. It is estimated his process will take two to three months.
Sponsors
Children's Hospital Foundation
Eligibility
Sex/Gender
All
Age
0 to 18 Years
Healthy volunteers
No
Inclusion criteria
Eligibility criteria for Validation Phase: Inclusion criteria • Age less than or equal to 18 years old at the time of biospecimen collection for PRISM/ZERO/ZERO2 report. • Subjects enrolled in PRISM/ZERO/ZERO2 with a final molecular profiling report. Eligibility criteria for User Evaluation Phase: Inclusion criteria • Age less than or equal to18 years old at the time of consent for this study and at the time of biospecimen collection for PRISM/ZERO/ZERO2 report. • Subjects can be enrolled in OSCAR at any time after their PRISM/ZERO/ZERO2 consent and before curation clinicians receive their molecular profiling results. Note: PRISM/ZERO/ZERO2 reports are the molecular profiling reports generated by the Zero Childhood Cancer Program.
Exclusion criteria
Patients with inconclusive or indeterminate molecular profiling results due to poor tissue quality or any other issues related to tissues collection and/or laboratory testing.
Outcome results
None listed